Ocriplasmin in vitreomacular traction syndrome – own experience

Abstract

Ocriplasmin influence on posterior vitreous detachment (PVD) and vitreomacular traction (VMT) at patients treated in Ophthalmology and Ocular Oncology Clinic of University Hospital was evaluated. The paper presents results of the best corrected visual acuity (BCVA), images of swept source optic coherence tomography (OCT) and our experiences related with employment ocriplasmin at 4 patients. Patients were evaluated according to new classification of Vitreomacular Interface (VMI).

Material and methods: Four patients (4 eyes with vitreomacular traction) were treated with 0,125 mg ocriplasmin (jetrea 0,5 mg/0,2 ml) intravitreal iniection. Duration of clinical signs of symptoms, the degree of disease severity (according to International Traction Study, IVTS, Group), presence of posterior vitreous detachment and resolution of vitreomacular traction and best corrected visual acuity (BCVA) improvement were evaluated. BCVA, ophthalmoscopy using Volk lens and swept source optical coherent tomography (OCT) were performed in all patients.

Results: In 2 eyes (50%) total posterior vitreous detachment and vitreomacular traction was achieved. The BCVA improvement, withdrawn of symptoms, central scotomas and metamorphopsies were observed in patients. It has undergone decrease of vitreomacular traction after treatment at one patient 25%, central scotomas and metamorphopsies. We observe no changes at one patient after employed treatment (25%). The vitreous body detachment events (lasting 1 day vitreous floaters, photopsia, floaters) appeared in all treated patients. Subretinal fluid absorption and BCVA improvement were observed in effective treated patients during follow-up. No one patient had present treatment related complications.

Conclusions: Enzymatic vitreolysis with ocriplasmin for vitreomacular traction is effective and safe treatment, which can be alternative management for both strategies: “watch and wait” or vitrectomy.